DexCom to Take Its Technology International

DexCom (NASDAQ: DXCM) might just have significant untapped potential and even greater growth ahead. In this clip from "3 Minute Stocks Updates" on Motley Fool Live, recorded on Feb. 16, Motley Fool contributors Brian Feroldi and Brian Withers discuss why DexCom investors are keeping a close watch on the company for two main reasons.

{% sfr %}

Brian Feroldi: For now, all eyes remain on two things with DexCom. The first thing to keep an eye on is the launch of the G7, so this is the company's next generation sensing technology. There are all benefits to it. It's factory-calibrated. It's going to be a significant reduction in manufacturing costs and even more accurate than the current methodology, so management is really pumped about this system. Second, they are taking their current technology called the G6 and they're actually selling it in international markets such as Bulgaria, Estonia, Latvia, and Lithuania at a discounted price. They're taking their existing technology and allowing people around the world who don't have access to reimbursement and are far more price-sensitive to use this technology which is really cool and could be a long-term driver of growth for the company. However, doing so is likely to be a short-term drag on the company's margins until they get that up in scale. But if you look at the big picture for investors, revenue is trending in the right direction, 70% of this company's revenue is recurring from the sensors and the opportunity ahead of this company still remains large.

Brian Withers: Brian, I didn't realize on that slide you shared with the G7, the product is actually pictured there. Can you pop that up again?

Feroldi: Yes.

Withers: I was focusing on the iPhone [Apple (NASDAQ: AAPL)] app and I totally missed it. Wow, that is super cool.

Feroldi: It's the size of a quarter essentially.

Withers: Fantastic. I was reading through the press release and they said they've submitted a 510(k) pre-market notification to the U.S. FDA for regulatory review of the G7. They said data in the submission highlighted industry-leading precision including mean, absolute relative difference from the pivotal trial as follows: adults, 8.2%, pediatrics, 8.1%. What does all of that mean?

Feroldi: Yes. I love that science talk. A 510(k) is a type of FDA approval that you can go for, basically saying, this isn't a brand-new device. This is substantially equivalent to an existing device that's on the market, aka their G6. Therefore, the regulatory requirements to get the thumbs-up are far less than it would be if it was a brand-new device that the FDA had ever seen before, so that's 510(k). MARD, mean absolute relative difference, is the difference between what the sensor says your blood glucose is, and what your blood glucose actually is, as measured by the labs. That's one downside to using sensor technologies. Sensor technology is not as accurate as fingerprint technology when you're applying actual blood dropped to it. However, the analogy that I've heard, which I just absolutely love, is imagine you were on a road in a car and your task is to drive this car straight for the rest of your life. In the old technology, pricking your finger, you only get to look out of your front dash once every four hours or so to tell what direction you are in. Are you left or are you right? Would you rather do that, or would you rather look out of a dash that's in real time but blurry? Which of those do you think will allow you to stay on the road better? Well, the blurry is the continuous glucose monitoring and you getting real-time feedback about the direction of your blood glucose is incredibly valuable. What they're saying with that MARD thing is, it's blurry, but it's less blurry than previous versions of the system. Again, they have continually every time come out with a new version of their system. The accuracy gets better and better, so essentially the screen that you're seeing out of gets less and less blurry.

10 stocks we like better than DexCom
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and DexCom wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of March 3, 2022

Brian Feroldi has no position in any of the stocks mentioned. Brian Withers has no position in any of the stocks mentioned. The Motley Fool owns and recommends Apple. The Motley Fool recommends DexCom and recommends the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More